Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.

Marketed Products:
Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. We use our expertise to register approved drugs with regulatory agencies in the country we have acquired the rights for; and then, upon regulatory approval, we distribute, market and sell these products. Our efforts are focused on speciatlist physicians in private practice or at hospitals and major medical centers in our territories. Below is a description of our in-licensed products.

NARCOTIC ANALGESICS
(PAIN RELIEF MEDICATIONS)
TERRITIORIES
PRODUCT DESCRIPTION AND DOSAGE

ORAMORPH®
(morphine sulphate)
Oral Solution

ORAMORPH® (Orr-a-morf) is morphine sulphate in an oral solution and is used for managing moderate to severe chronic pain for more than a few days. It works by dulling the pain perception center in the brain.

  • Greece
  • Cyprus
 ORAMORPH® (Orr-a-morf) is morphine sulphate in an oral solution and is used for managing moderate to severe chronic pain for more than a few days. It works by dulling the pain perception center in the brain. Oramorph® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is marketed by Molteni in Italy.

Oramorph® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is owned by Molteni Farmaceutici, Inc. and marketed by Molteni Farmaceutici, Inc. in Italy.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Oramorph® in the countries of Greece and Cyprus.

Currently, Oramorph has a Greek marketing authorization. Oramorph can only be sold in Greece via a centralized government tender. Samaritan is preparing a tender application for the next request by Greek authorities for applications.


MORPHINE SULPHATE®
(morphine sulphate)
Injectable Form
MORPHINE SULPHATE ® (mor-fene sul-fate) relieves moderate to severe pain by binding to brain receptors. Morphine Sulphate may be used to control the pain following surgery, child birth, and other procedures. It may also be used to treat the pain associated with cancer, heart attacks, sickle cell disease and other medical conditions.

  • Greece
  • Cyprus
 MORPHINE SULPHATE ® (mor-fene sul-fate) relieves moderate to severe pain by binding to brain receptors. Morphine Sulphate may be used to control the pain following surgery, child birth, and other procedures. It may also be used to treat the pain associated with cancer, heart attacks, sickle cell disease and other medical conditions.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Morphine Sulphate® in the countries of Greece and Cyprus. Samaritan has received its first tender purchase order of Morphine Sulfate and Pethidine from the Institute of Pharmaceutical Research and Technology (IFET).

Currently, Morphine Sulphate® can only be sold in Greece and Cyprus via a centralized government tender. Samaritan is preparing a tender application for the next request by Greek authorities for applications.


PETHIDINE®
(peth-i-dine)
Injectable Form

PETHIDINE ® (peth-i-dine) indicated for the treatment of moderate to severe pain, and may be prescribed as a preoperative medication, support of anesthesia, and obstetric analgesia.

  • Greece
  • Cyprus
 PETHIDINE ® (peth-i-dine) indicated for the treatment of moderate to severe pain, and may be prescribed as a preoperative medication, support of anesthesia, and obstetric analgesia.

Samaritan has received its first tender purchase order of Morphine Sulfate and Pethidine from the Institute of Pharmaceutical Research and Technology (IFET).

Currently, Pethidine® can only be sold in Greece and Cyprus via a centralized government tender. Samaritan is preparing a tender application for the next request by Greek authorities for applications.

RAPYDAN®
(lidocaine 70 mg and tetracaine 70 mg)
Topical Anesthetic Patch

RAPYDAN® (Rap-e-dan) Rapydan® is indicated for local dermal analgesia on intact skin, and consists of a thin, uniform, local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetic. The drug formulation is an eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. Rapydan® is indicated to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions.
  • Greece
  • Cyprus

RAPYDAN® (Rap-e-dan) Rapydan® is indicated for local dermal analgesia on intact skin, and consists of a thin, uniform, local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetic. The drug formulation is an eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. Rapydan® is indicated to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions.

On August 3, 2007, Samaritan signed an exclusive agreement with EUSA for the marketing and distribution of the product RAPYDAN® in Greece and Cyprus. Rapydan® is an approved FDA prescription product under the name SYNERA® and is owned by ZARS Pharmaceuticals, Inc. and marketed by Endo Pharmaceuticals, Inc. in the US.

Currently, Samaritan Pharmaceuticals is utilizing the US FDA approved regulatory file in preparing marketing applications for Rapydan® with regulatory authorities in Greece and Cyprus to gain country marketing authorization drug approval.
DRUG ADDICTION THERAPY
TERRITIORIES
PRODUCT DESCRIPTION AND DOSAGE

METHADONE HCL®
(methadone hydrochloride)
Oral Solution Presentations
 METHADONE HCL® (meth-a-done) is an opiate agonist. Methadone HCL® prevents heroin or morphine from interacting with receptors for natural painkillers called endorphins, blocking the effects of the addictive drugs and reducing the physical cravings. Methadone HCL® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is owned by Molteni Pharmaceuticals, Inc. and marketed by Molteni Farmaceutici, Inc. in Italy.

  • Greece
  • Cyprus
 METHADONE HCL® (meth-a-done) is an opiate agonist. Methadone HCL® prevents heroin or morphine from interacting with receptors for natural painkillers called endorphins, blocking the effects of the addictive drugs and reducing the physical cravings. Methadone HCL® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is owned by Molteni Pharmaceuticals, Inc. and marketed by Molteni Farmaceutici, Inc. in Italy.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Methadone HCL® in the countries of Greece and Cyprus.

Currently, Methadone HCL® can only be sold in Greece and Cyprus via a centralized government tender. Samaritan is preparing a tender application for the next request by Greek authorities for applications.

NALOXONE MOLTENI®
(naloxone hydrochloride)
Injectable Form

NALOXONE MOLTENI ® (nal-ox-own) is an opioid antagonist which reverses the effects of opioid overdose, for example heroin and morphine overdose. Specifically, Naloxone is used in opioid overdoses for countering life-threatening depression of the central nervous system and respiratory system.

  • Greece
  • Cyprus
 NALOXONE MOLTENI ® (nal-ox-own) is an opioid antagonist which reverses the effects of opioid overdose, for example heroin and morphine overdose. Specifically, Naloxone is used in opioid overdoses for countering life-threatening depression of the central nervous system and respiratory system.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Naloxone Molteni ® in the countries of Greece and Cyprus.

Currently, Naloxone Molteni® will be sold and distributed by Samaritan on a named patient basis until the pricing and the reimbursement of Naloxone Molteni® is established in Greece and Cyprus, with the relevant regulatory authorities.

NALTREXONE HCL®
(naltrexone hydrochloride)
Oral Tablet Form

  • Greece
  • Cyprus
 NALTREXONE® (nal-trex-own) is an opioid antagonist which is used to help people who have a narcotic or alcohol addiction stay drug free. Naltrexone HCL® is used after the patient has stopped taking drugs or alcohol. It works by blocking the effects of narcotics or by decreasing the craving for alcohol.

Naltrexone HCL® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is owned by Molteni Farmaceutici, Inc. and marketed by Molteni Farmaceutici, Inc. in Italy.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Naltrexone HCL® in the countries of Greece and Cyprus.

Currently, Samaritan Pharmaceuticals is utilizing the Italian Ministry of Health approved regulatory file in preparing marketing applications for Naltrexone HCL® with regulatory authorities in Greece and Cyprus to gain country marketing authorization drug approval.
ANESTHESIA
TERRITIORIES
PRODUCT DESCRIPTION AND DOSAGE

MEPIVAMOL®
(Mepivacaine)
Injectable Form

MEPIVAMOL® (Me-piv-a-mol) is an effective and reliable local anesthetic of intermediate duration and low systemic toxicity. It is widely used for regional anesthetic procedures such as IVRA, infiltration, epidural blockade, plexus and peripheral nerve blockade.

  • Greece
  • Cyprus
 MEPIVAMOL® (Me-piv-a-mol) is an effective and reliable local anesthetic of intermediate duration and low systemic toxicity. It is widely used for regional anesthetic procedures such as IVRA, infiltration, epidural blockade, plexus and peripheral nerve blockade. Mepivamol® is approved by the Italian Ministry of Health (The equivalent to the US FDA) and is owned by Molteni Farmaceutici, Inc. and marketed by Molteni Farmaceutici, Inc. in Italy.

On January 1, 2007, Samaritan entered into an exclusive licensing agreement with Molteni Farmaceutici for the marketing and distribution of Mepivamol® in the countries of Greece and Cyprus. Currently, Samaritan Pharmaceuticals is utilizing the Italian Ministry of Health approved regulatory file in preparing marketing applications for Mepivamol® with regulatory authorities in Greece and Cyprus to gain country marketing authorization drug approval.
More products coming soon...